Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov;30(13):1578-1591.
doi: 10.1177/13524585241257843. Epub 2024 Sep 30.

Topical review: Lactation and use of DMTs in women with MS

Stephanie Hsu  1 , Ayushi Balan  1 , Riley Bove  1
Affiliations
Review

Topical review: Lactation and use of DMTs in women with MS

Stephanie Hsu et al. Mult Scler. 2024 Nov.

Abstract

One in three females with multiple sclerosis (MS) becomes pregnant after diagnosis. In the postpartum period, there is a risk of rebound inflammatory activity. This risk can likely be reduced with breastfeeding, as well as with early initiation of effective therapies that have low therapeutic lag. To guide patients in their choices surrounding breastfeeding and MS therapies, clinicians must be familiar with how best to protect against relapses, to ensure infant safety, and to support breastfeeding choices. This topical review provides a broad framework on lactation in women with MS. It seeks to reframe guidelines around caring for the maternal-infant dyad, and for diverse populations living with MS. It also provides updated data on the effects of lactation in women with MS and the limited data on transfer of disease-modifying therapies (DMTs) into breastmilk. The ultimate goal is to support informed shared decision-making between clinicians and patients regarding breastfeeding during the high-risk postpartum period.

Keywords: Lactation; amenorrhea; breastmilk; mother–infant dyad; reproductive safety.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: S.H. and A.B. report no conflicts. R.B. has received research support from Biogen, Roche Genentech, and Novartis as well as from the NMSS, NIH, and DOD. She receives consulting and/or advisory board fees from Alexion, EMD Serono, Horizon, Jansen, and TG Therapeutics.

Similar articles

See all similar articles

Cited by

References

    1. Koch-Henriksen N, Magyari M. Apparent changes in the epidemiology and severity of multiple sclerosis. Nat Rev Neurol 2021; 17(11): 676–688. - PubMed
    1. Ford H. Clinical presentation and diagnosis of multiple sclerosis. Clin Med 2020; 20: 380–383. - PMC - PubMed
    1. Mendibe Bilbao M, Boyero Durán S, Bárcena Llona J, et al.. Multiple sclerosis: Pregnancy and women’s health issues. Neurologia 2019; 34(4): 259–269. - PubMed
    1. Houtchens M, Mahlanza T, Ciplea AI, et al.. Peginterferon beta-1a concentrations in breast milk of lactating multiple sclerosis patients. Mult Scler Relat Disord 2022; 60: 103700. - PubMed
    1. Proschmann U, Thomas K, Thiel S, et al.. Natalizumab during pregnancy and lactation. Mult Scler 2018; 24: 1627–1634. - PubMed

Substances